Anmelden Kostenlos registrieren

SinoMab BioScience RPE

Was ist das RPE von SinoMab BioScience?

RPE von SinoMab BioScience Limited ist -¥7.86

Was ist die Definition von RPE?

Umsatz pro Mitarbeiter (RPE) ist der Umsatz geteilt durch die Anzahl der Mitarbeiter einer Organisation.

RPE von Unternehmen in Health Care Sektor auf HKSE im Vergleich zu SinoMab BioScience

Was macht SinoMab BioScience?

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.

Unternehmen mit rpe ähnlich SinoMab BioScience